ure system will be utilized for blood collection and culture and it is expected that at least 40,000 TruCulture tubes will be required to characterize the immune responses of the 1,000 participants. TruCulture is designed to capture immune cell activity while avoiding many of the variables often associated with sample collection and manipulation. An important advantage of this collection system is that cell stimulations are performed instantly, at the point of collection, which provides a more accurate snapshot of the subject's immune response. The use of TruCulture will allow researchers to describe individual differences at the genomic, proteomic, and inflammation pathway levels. The involvement of Rules-Based Medicine, Inc. as a partner will ensure timely development of new assays and application to relevant diseases.
On April 27, 2011, Myriad Genetics (Nasdaq: MYGN) of Salt Lake City, a leader in molecular diagnostics, announced an agreement to acquire Rules-Based Medicine. The transaction is expected to be complete by May 31, 2011. RBM headquarters will remain in Austin, TX and will operate as a wholly owned subsidiary of Myriad Genetics under the name Myriad RBM.
About Rules Based-Medicine, Inc.
Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunolog
'/>"/>
SOURCE Rules-Based Medicine, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development2.
Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development3.
Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel4.
Penn-led collaboration mimics library of bio-membranes for use in nanomedicine, drug delivery5.
Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership6.
Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.7.
Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project8.
Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for Best and Brightest Forum on Medical Innovation9.
Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial10.
Aperio Partners with Definiens to Market Definiens Tissue Studio for Advanced Image Analysis11.
John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners